Genetically engineered dendritic cell-based cancer vaccines (review)

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Dendritic cells (DCs) are potent antigen-presenting cells crucial for initiating T cell responses.
• Their antigen-presenting capacity makes DCs attractive for therapeutic cancer vaccine development.
• Tumor-bearing individuals often exhibit impaired DC tumor antigen presentation, necessitating alternative strategies.

Purpose of the Study:

• To review methods for creating and utilizing genetically engineered DC-based cancer vaccines.
• To evaluate the therapeutic outcomes of these engineered DC vaccines.
• To discuss the future prospects and limitations of DC-based cancer vaccination.

Main Methods:

• Directly loading DCs with oncoproteins in vitro to bypass endogenous presentation defects.
• Genetic manipulation of DCs via transfection with DNA or RNA encoding tumor-associated antigens (TAAs) or immunostimulatory molecules.
• Utilizing viral vectors (retrovirus, adenovirus, poxvirus) for gene delivery into DCs.
• Employing fusion of DCs with tumor cells to create hybrid cell-based vaccines.

Main Results:

• Genetic modifications and various delivery methods have shown efficiency in experimental tumor models.
• Gene delivery into DCs using viral vectors has been successfully applied for therapy.
• Hybrid cell-based vaccines derived from DC-tumor cell fusion demonstrated significant therapeutic activity, including in cancer patients.

Conclusions:

• Genetically engineered DCs represent a viable approach to enhance cancer vaccine efficacy.
• Direct loading, genetic manipulation, and cell fusion are effective strategies for DC-based cancer immunotherapy.
• Further research into the prospects and limitations is essential for clinical translation.